This facilitates the company&rsquo s delivery of surgical technologies to healthcare systems in South-east Asia, UltraGreen.ai says

 

[SINGAPORE] Surgical technology firm UltraGreen.ai has secured dual market regulatory approvals for two of its products less than a month since its trading debut on the Singapore Exchange. 

 

It clinched approvals for Verdye, a fluorescence dye used in fluorescence-guided surgery, in the Philippines. 

 

It also secured approval for IC-Flow Imaging System V2 &ndash a medical infrared camera system that captures fluorescent images in surgical procedures, in Malaysia. 

 

On Tuesday (Dec 30), the company said the approvals mark an &ldquo important step&rdquo in its strategic expansion across South-east Asia, where healthcare demand is growing. 

 

This comes as UltraGreen.ai aims to expand the use of fluorescence-guided surgery &ndash which has become an increasingly important tool across surgical procedures and specialties &ndash in the region. 

 

Declan Cassells, chief operating officer of UltraGreen.ai, said that the approvals will facilitate the company&rsquo s delivery of surgical technologies to healthcare systems across the South-east Asia. 

 

&ldquo With these approvals in place, UltraGreen.ai and its local partners can now actively support education, training and broader clinical adoption of indocyanine green-based techniques among surgeons in both markets,&rdquo the company said. 

 

Beyond regulatory approvals, the company said that it is growing its footprint in the region via clinical partnerships and market access initiatives.

 

Quek Mei Ling, chief business officer for Asia-Pacific at UltraGreen.ai, noted that the approvals come as South-east Asia is experiencing a rise in surgical procedures across oncology, colorectal and reconstructive care. 

 

Hsieh Fu Hua, an independent director of newly-listed UltraGreen.ai, has again bought more shares of the company.

 

On Dec 12, Hsieh, a former CEO of SGX, paid US$1.44 each for 120,000 shares.

 

This brings his total holdings to 300,000 shares. He first bought the company' s shares on Dec 9, paying US$1.39 each.

 

In a separate announcement, co-manager of the IPO, Citibank, had on Dec 12 bought 1,519,700 shares, as part of its latest stabilising action.

 

The shares were bought at between US$1.43 to US$1.45.

 

With this, the IPO managers have bought all 20,689,700 shares as part of the post-listing stabilisation mandate, and that the over-allotment option will not be exercised.

 

Its IPO two weeks ago was priced at US$1.45.

 

 

Date of Purchases: 4 December 2025
Total Number of Shares Purchased: 1,820,000 shares
Price Range of Purchases: US$1.45